🔴 Live from #EHA2026 Congress: EORTC-GIMEMA AML 21 Phase 3 trial analysis shows pre‑treatment HRQoL independently predicts survival in Older Adults with Acute Myeloid Leukemia, supporting the incorporation of PROs in fitness criteria. #PatientReportedOutcomes

0 likes 0 replies